A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia

Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinical...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2015-06, Vol.15 (6), p.377-383
Main Authors: Mannis, Gabriel N, Andreadis, Charalambos, Logan, Aaron C, Damon, Lloyd E, Benet, Leslie Z, Ai, Weiyun Z, Gaensler, Karin M.L, Kaplan, Lawrence D, Koplowicz, Yelena B, Linker, Charles A, Olin, Rebecca L, Sayre, Peter H, Smith, Catherine C, Sudhindra, Akshay, Venstrom, Jeffrey M, Wolf, Jeffrey L, Martin, Thomas G
Format: Article
Language:English
Subjects:
Acute Myelogenous Leukemia
Administration, Intravesical
Adult
Area Under Curve
Autologous transplant
Busulfan - administration & dosage
Busulfan - adverse effects
Busulfan - pharmacokinetics
Disease-Free Survival
Etoposide - administration & dosage
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Transplantation
High-dose chemotherapy
Humans
Leukemia, Myeloid, Acute - therapy
Maximum Tolerated Dose
Middle Aged
Mucositis - chemically induced
Myeloablative Agonists - administration & dosage
Myeloablative Agonists - adverse effects
Myeloablative Agonists - pharmacokinetics
Pharmacokinetics
Phase I Clinical Trial
Recurrence
Transplantation Conditioning - methods
Transplantation, Autologous
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinically acceptable dose. This busulfan AUC target might be associated with improved relapse-free survival.
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2015.02.016